亞太和中東 NGS 市場按產品、工作流程、平台、吞吐量、技術類型、應用、最終用戶和國家分類的分析和預測（2025 年至 2035 年）

亞太和中東地區的次世代定序(NGS) 市場正在經歷顯著成長，這得益於次世代定序技術的快速發展、遺傳病和癌症患病率的上升以及次世代定序在精準醫療中的應用不斷擴大。

次世代定序平台的持續創新正在提高效率、準確性和成本效益，使得次世代定序更適用於臨床診斷和研究目的。個人化醫療的需求不斷成長，尤其是腫瘤學、生殖健康和感染疾病診斷領域的次世代定序，進一步推動了市場擴張。此外，強力的政府舉措、不斷增加的研發投入以及生物技術公司和醫療保健提供者之間的戰略合作夥伴關係正在推動該地區次世代定序的發展。中國、印度和沙烏地阿拉伯等國家正在主導大型基因組計劃，以推動早期疾病檢測和精準醫療，進一步加強了亞太和中東地區的NGS市場前景。

次世代定序市場具有巨大的成長潛力，但也存在一些挑戰。與次世代定序平台、消耗品和資料分析工具相關的高成本仍然是一個重大障礙，尤其是在低收入社區。生物資訊學和基因組資料解釋專家的短缺進一步阻礙了次世代定序技術的廣泛應用。此外，對資料隱私、安全和法規遵循的擔憂增加了不同國家實施次世代定序的複雜性。此外，醫療保健法規的差異以及對基因組資料使用的倫理問題的擔憂也成為市場的額外限制因素，使得某些地區採用次世代定序變得更具挑戰性。這項因素對亞太和中東的NGS市場構成了挑戰。

然而，亞太和中東地區的次世代定序市場仍有巨大的擴張機會。醫療基礎設施快速改善的新興國家對次世代定序的研究和臨床應用的投資正在增加。人工智慧 (AI) 與雲端基礎的生物資訊學的融合正在徹底改變基因組資料分析，使得次世代定序更有效率、更容易取得。此外，次世代定序在非侵入性產前檢測（NIPT）和感染疾病研究中日益廣泛的應用為市場參與企業提供了新的成長途徑。隨著政府和私人公司繼續投資基因組研究、精準醫療和臨床應用，亞太和中東地區的次世代定序市場預計將在未來幾年大幅擴張。

本報告研究了亞太和中東的NGS市場，並概述了市場以及關鍵細分市場，例如產品、工作流程、平台、吞吐量、技術類型、應用、最終用戶、國家趨勢和公司簡介。

目錄

執行摘要

研究範圍

調查方法

第 1 章 亞太與中東 NGS 市場概述

• 市場展望
• 產業展望
• 市場動態

2. 亞太地區和中東 NGS 市場分析（按產品分類），百萬美元，2024 年至 2035 年

• 耗材
• 裝置
• 服務

3. 亞太地區和中東 NGS 市場分析（按工作流程），百萬美元，2024 年至 2035 年

• 定序
• 前序
• 資料分析

4. 亞太地區和中東 NGS 市場分析（按平台），百萬美元，2024-2035 年

• 概述
• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies plc.
• 其他公司

5. 亞太地區和中東 NGS 市場分析（按吞吐量，百萬美元，2024 年至 2035 年）

• 概述
• 高吞吐量
• 中等吞吐量
• 低吞吐量

6. 亞太地區和中東 NGS 市場分析（按技術類型，百萬美元，2024 年至 2035 年）

• 合成定序
• Ion Torrent 半導體定序
• 單分子即時定序
• 奈米孔定序技術
• 其他

7. 亞太地區和中東 NGS 市場分析（按應用分類），百萬美元，2024 年至 2035 年

• 臨床診斷
• 轉化研究

8. 亞太地區和中東 NGS 市場分析（按最終用戶分類，百萬美元，2024 年至 2035 年）

• 製藥和生物技術公司
• 學術研究所
• 臨床實驗室
• 其他

9. 亞太地區 NGS 市場分析（按國家/地區分類，百萬美元，2024 年至 2035 年）

• 市場概況
• 市場規模及預測
  • 日本
  • 中國
  • 印度
  • 韓國
  • 澳洲
  • 新加坡
  • 紐西蘭
  • 其他

10. 中東 NGS 市場分析（按國家/地區），百萬美元，2024 年至 2035 年

• 市場概況
• 市場規模及預測
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 以色列
  • 埃及
  • 其他

第 11 章亞太和中東 NGS 市場競爭基準化分析和公司概況

• 競爭性基準化分析
• 競爭格局
  • 各公司的主要策略和發展
  • 2024 年至 2035 年市場佔有率分析
  • 亞太地區和中東NGS市場最終用戶成長佔有率分析
  • 亞太和中東 NGS 市場成長佔有率分析（按吞吐量）
• 公司簡介
  • BGI Group
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Pacific Biosciences of California, Inc.
  • Oxford Nanopore Technologies plc
• 新興企業（亞太和中東）

Asia-Pacific and Middle East NGS Market Industry Overview

The Asia-Pacific and Middle East Next-Generation Sequencing (NGS) market is experiencing significant growth, driven by rapid advancements in next-generation sequencing technologies, the rising prevalence of genetic disorders and cancer, and the expanding application of next-generation sequencing in precision medicine. Continuous innovations in next-generation sequencing platforms have enhanced efficiency, accuracy, and cost-effectiveness, making next-generation sequencing more accessible for both clinical diagnostics and research purposes. The increasing demand for next-generation sequencing in personalized medicine, particularly in oncology, reproductive health, and infectious disease diagnostics, is further fueling market expansion. Additionally, strong government initiatives, increased R&D investments, and strategic collaborations between biotech firms and healthcare providers are propelling the growth of next-generation sequencing in the region. Countries such as China, India, and Saudi Arabia are leading large-scale genomic projects to advance early disease detection and precision healthcare, further strengthening the Asia-Pacific and Middle East NGS market landscape.

Despite the strong growth potential of the next-generation sequencing market, several challenges persist. The high cost associated with next-generation sequencing platforms, consumables, and data analysis tools remains a major barrier, particularly in low-income regions. The shortage of skilled professionals proficient in bioinformatics and genomic data interpretation further hinders the widespread adoption of next-generation sequencing technologies. Moreover, concerns related to data privacy, security, and regulatory compliance create complexities in the implementation of next-generation sequencing across different countries. Additionally, variations in healthcare regulations and ethical concerns surrounding genomic data usage add to the market's constraints, making the adoption of next-generation sequencing more challenging in certain regions. This factor is posing a challenge for the Asia-Pacific and Middle East NGS market.

Nevertheless, the next-generation sequencing market in the Asia-Pacific and Middle East regions presents significant opportunities for expansion. Emerging economies with rapidly improving healthcare infrastructure are increasingly investing in next-generation sequencing research and clinical applications. The integration of artificial intelligence (AI) and cloud-based bioinformatics is revolutionizing genomic data analysis, making next-generation sequencing more efficient and accessible. Furthermore, the growing use of next-generation sequencing in non-invasive prenatal testing (NIPT) and infectious disease research offers new growth avenues for market players. As governments and private sector companies continue investing in genomic research, precision medicine, and clinical applications, the next-generation sequencing market in Asia-Pacific and the Middle East is poised for substantial expansion in the coming years.

Impact of COVID-19

Next-generation sequencing (NGS)-based products play a vital role in disease research and diagnostics, particularly in cancer detection and treatment, where next-generation sequencing enables personalized and targeted therapies for patients. The next-generation sequencing market is primarily driven by manufacturers of next-generation sequencing instruments, kits, assays, and service providers offering gene panels and oncology-focused testing services using next-generation sequencing technology. However, the COVID-19 pandemic negatively impacted revenue growth in the next-generation sequencing market due to disruptions in supply chains and healthcare operations, affecting the availability of next-generation sequencing products and services.

Despite these challenges, the pandemic underscored the critical role of next-generation sequencing in public health management, particularly in sequencing the SARS-CoV-2 virus, tracking its mutations, and monitoring population health. For example, in October 2022, Kyrgyzstan initiated efforts to enhance its next-generation sequencing capabilities for SARS-CoV-2 surveillance. Industry leaders in next-generation sequencing anticipate a shift toward local manufacturing to reduce dependence on imports, as the pandemic exposed weaknesses in global supply chains. Consequently, several countries in the Asia-Pacific and Middle East regions are prioritizing domestic production of essential medical supplies and next-generation sequencing tools to ensure a more stable and resilient healthcare infrastructure, propelling the the overall Asia-Pacific and Middle East NGS market.

The growth of the next-generation sequencing market is fueled by the increasing adoption of next-generation sequencing in diverse research and diagnostic applications, the rising prevalence of non-communicable diseases, and continuous advancements in next-generation sequencing platforms that enhance efficiency, speed, and accuracy. As the demand for next-generation sequencing continues to rise, innovations in next-generation sequencing technology will further drive market expansion, positioning next-generation sequencing as a fundamental tool in modern genomics and precision medicine.

Market Segmentation:

Segmentation 1: by Offerings

• Consumables
• Equipment
• Services

The Asia-Pacific and Middle East NGS market (by offerings) is expected to be dominated by the consumables segment.

Segmentation 2: by Platform

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Pacific BioSciences of California, Inc.
• Oxford Nanopore Technologies plc.
• Other Companies

The Asia-Pacific and Middle East NGS market (by platform) is expected to be dominated by Illumina, Inc.

Segmentation 3: by Throughput

• High-Throughput
• Medium-Throughput
• Low-Throughput

The Asia-Pacific and Middle East NGS market (by throughput) is expected to be dominated by the high-throughput segment.

Segmentation 4: by Technology Type

• Sequencing by Synthesis
• In Torrent Semiconductor Sequencing
• Single Molecule Real-Time Sequencing
• Nanopore Sequencing Technology
• Other Technologies

The Asia-Pacific NGS market (by technology type) is expected to be dominated by the sequencing by synthesis segment.

Segmentation 5: by Application

• Clinical Diagnostics
• Translational Research
• Other Applications

The Asia-Pacific NGS market (by technology type) is expected to be dominated by the translational research segment.

Segmentation 6: by End User

• Academic and Research Institutes
• Clinical Laboratories
• Pharmaceutical and Biotechnology Companies
• Other End Users

The Asia-Pacific NGS market (by end user) is expected to be dominated by the academic and research insitutes segment.

Segmentation 7: by Country

• Asia-Pacific
  • Japan
  • India
  • South Korea
  • Australia
  • Singapore
  • New Zealand
  • Rest-of-Asia-Pacific
• Middle East
  • U.A.E.
  • K.S.A.
  • Egypt
  • Israel
  • Rest-of-Middle East

The Asia-Pacific NGS market (by country) is expected to be dominated by Japan and the Middle East NGS market (by country) is expected to be dominated by the U.A.E.

Recent Developments in the Asia-Pacific and Middle East NGS Market

• In October 2022, PacBio introduced Revio and Onso, two new sequencing systems. Revio is a long-read sequencing system capable of sequencing up to 1,300 human whole genomes annually, while Onso is a benchtop short-read DNA sequencing platform. These systems enhance the scalability of PacBio's HiFi sequencing technology, supporting large-scale studies in human genetics, oncology, and agricultural genomics.
• In September 2022, Illumina, Inc. launched Illumina Complete Long-Reads (INFINITY) for whole-genome sequencing (WGS). This innovation provided a high-performance, fully integrated sequencing method, compatible with all NovaSeq systems, enabling the synthesis of thousands of long-read genomes per year.
• Also in September 2022, Illumina, Inc. unveiled the NovaSeq 6000 Dx, the first FDA-registered and CE-marked high-throughput in vitro diagnostic (IVD) sequencer. Designed for clinical applications, this platform ensures high compliance standards while delivering critical insights to improve patient care.
• In August 2022, Illumina, Inc. partnered with the Minderoo Foundation, investing $27.8 million to advance genetic research on marine ecosystems. This collaboration utilized Illumina's NextSeq 2000 sequencing system to analyze marine biodiversity and better understand oceanic life.
• In April 2022, Genomics England extended its partnership with a sequencing company to explore the therapeutic and scientific potential of comprehensive genomic analysis of cancer tumors using nanopore sequencing technology as part of an ongoing project.
• In March 2022, a sequencing company launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, a fully automated system capable of generating sequencing data within a single day, streamlining diagnostic processes.
• In January 2022, Pacific Biosciences of California, Inc. collaborated with Genomics England to further the 100,000 Genomes Project by leveraging long-read sequencing technology to detect genetic variants in cancer and rare disease cases. As part of this initiative, Genomics England re-sequenced biobank samples to identify additional genomic variations that short-read sequencing technologies might not effectively capture.

Demand - Drivers and Limitations

The following are the drivers for the Asia-Pacific and Middle East NGS market:

• Increasing Adoption of NGS in Various Research and Diagnostics Field
• Growing Prevalence of Non-Communicable Diseases is Boosting the Demand for NGS
• Advancement in the Performance of NGS Platforms

The market is expected to face some limitations as well due to the following challenges:

• Dearth of Skilled Professionals in Middle East Countries
• High Cost of Installation and Maintenance of the Equipment
• Reimbursement and Regulatory Policies of NGS

How can this report add value to an organization?

Type: The Asia-Pacific and Middle East NGS market has been extensively segmented on the basis of various categories such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Synergistic activities and product launches/approvals accounted for the maximum number of key developments, i.e., over 70% of the total developments in the global Asia-Pacific and Middle East NGS market.

Competitive Strategy: The Asia-Pacific and Middle East NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share. Key players in the Asia-Pacific and Middle East NGS market analyzed and profiled in the study involve established and players that offer various kinds of NGS platforms, consumables, and services.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Asia-Pacific and Middle East NGS Market Overview

• 1.1 Market Outlook
  • 1.1.1 Definitions
  • 1.1.2 Inclusion and Exclusion Criteria
  • 1.1.3 Market Size, 2024 - 2035, $Million
  • 1.1.4 Key Findings
  • 1.1.5 Market Growth Scenario
    • 1.1.5.1 Realistic Scenario
    • 1.1.5.2 Optimistic Scenario
    • 1.1.5.3 Pessimistic Scenario
• 1.2 Industry Outlook
  • 1.2.1 NGS: Market Overview and Ecosystem
  • 1.2.2 Asia-Pacific and Middle East NGS: Overview
  • 1.2.3 Key Trends and Emerging Application of NGS in Asia-Pacific and Middle East
  • 1.2.4 Patent Analysis
  • 1.2.5 Pricing Analysis
    • 1.2.5.1 Instrument
    • 1.2.5.2 Consumables
  • 1.2.6 Supply Chain Analysis
    • 1.2.6.1 Key Entities in Supply Chain
  • 1.2.7 Regulatory Framework
    • 1.2.7.1 Asia-Pacific
    • 1.2.7.2 Middle East
  • 1.2.8 Genome Projects
    • 1.2.8.1 Asia-Pacific
      • 1.2.8.1.1 China
      • 1.2.8.1.2 Japan
      • 1.2.8.1.3 India
      • 1.2.8.1.4 South Korea
      • 1.2.8.1.5 Singapore
      • 1.2.8.1.6 Other Asian Countries
    • 1.2.8.2 Middle East
      • 1.2.8.2.1 UAE
      • 1.2.8.2.2 Qatar
      • 1.2.8.2.3 Saudi Arabia
      • 1.2.8.2.4 Kuwait
      • 1.2.8.2.5 Other Middle East Countries
• 1.3 Market Dynamics
  • 1.3.1 Market Drivers
    • 1.3.1.1 Impact Analysis
  • 1.3.2 Market Restraints
    • 1.3.2.1 Impact Analysis
  • 1.3.3 Market Opportunities

2. Asia-Pacific and Middle East NGS Market Analysis (By Offering), $Million, 2024-2035

• 2.1 Consumables
  • 2.1.1 Library Preparation and Reagents
  • 2.1.2 Sequencing Kits and Reagents
  • 2.1.3 Others
• 2.2 Equipment
• 2.3 Services
  • 2.3.1 Sequencing Services
  • 2.3.2 Data Management Services

3. Asia-Pacific and Middle East NGS Market Analysis (By Workflow), $Million, 2024-2035

• 3.1 Sequencing
• 3.2 Pre-Sequencing
• 3.3 Data Analysis

4. Asia-Pacific and Middle East NGS Market Analysis (By Platform), $Million, 2024-2035

• 4.1 Overview
  • 4.1.1 Asia-Pacific
  • 4.1.2 Middle East
• 4.2 Illumina, Inc. (Asia-Pacific and Middle East)
  • 4.2.1 iSeq
  • 4.2.2 MiniSeq
  • 4.2.3 MiSeq
  • 4.2.4 NextSeq
  • 4.2.5 NovaSeq
• 4.3 Thermo Fisher Scientific, Inc. (Asia-Pacific and Middle East)
  • 4.3.1 Ion PGM
  • 4.3.2 Ion Genestudio S5
  • 4.3.3 Ion Proton
  • 4.3.4 Ion Genexus
• 4.4 Pacific Biosciences of California, Inc. (Asia-Pacific and Middle East)
  • 4.4.1 Sequel II/IIe
• 4.5 Oxford Nanopore Technologies plc. (Asia-Pacific and Middle East)
  • 4.5.1 MinION
  • 4.5.2 GridION
  • 4.5.3 PromethION
• 4.6 Other Companies (Asia-Pacific and Middle East)

5. Asia-Pacific and Middle East NGS Market Analysis (By Throughput), $Million, 2024-2035

• 5.1 Overview
  • 5.1.1 Asia-Pacific
  • 5.1.2 Middle East
• 5.2 High-Throughput
• 5.3 Medium-Throughput
• 5.4 Low-Throughput

6. Asia-Pacific and Middle East NGS Market Analysis (By Technology Type), $Million, 2024-2035

• 6.1 Sequencing by Synthesis
• 6.2 Ion Torrent Semiconductor Sequencing
• 6.3 Single Molecule Real-time Sequencing
• 6.4 Nanopore Sequencing Technologies
• 6.5 Other Technologies

7. Asia-Pacific and Middle East NGS Market Analysis (By Application), $Million, 2024-2035

• 7.1 Clinical Diagnostics
  • 7.1.1 Oncology
  • 7.1.2 Infectious Diseases
  • 7.1.3 Reproductive Genetics
  • 7.1.4 Others
• 7.2 Translational Research
  • 7.2.1 Clinical
  • 7.2.2 Agricultural
  • 7.2.3 Others

8. Asia-Pacific and Middle East NGS Market Analysis (By End User), $Million, 2024-2035

• 8.1 Pharmaceutical and Biotechnology Companies
• 8.2 Academic and Research Institution
• 8.3 Clinical Laboratories
• 8.4 Others

9. Asia-Pacific NGS Market Analysis (By Country), $Million, 2024-2035

• 9.1 Market Overview
• 9.2 Market Sizing and Forecast
  • 9.2.1 Japan
  • 9.2.2 China
  • 9.2.3 India
  • 9.2.4 South Korea
  • 9.2.5 Australia
  • 9.2.6 Singapore
  • 9.2.7 New Zealand
  • 9.2.8 Rest of Asia-Pacific

10. Middle East NGS Market Analysis (By Country), $ Million, 2024-2035

• 10.1 Market Overview
• 10.2 Market Sizing and Forecast
  • 10.2.1 UAE
  • 10.2.2 KSA
  • 10.2.3 Israel
  • 10.2.4 Egypt
  • 10.2.5 Rest-of-Middle East

11. Asia-Pacific and Middle East NGS Market - Competitive Benchmarking and Company Profiles

• 11.1 Competitive Benchmarking
• 11.2 Competitive Landscape
  • 11.2.1 Key Strategies and Developments by Company
    • 11.2.1.1 Funding Activities
    • 11.2.1.2 Mergers and Acquisitions
    • 11.2.1.3 Regulatory Approvals
    • 11.2.1.4 Partnerships, Collaborations, and Business Expansions
  • 11.2.2 Market Share Analysis, 2024-2035
  • 11.2.3 Growth Share Analysis for Asia-Pacific and Middle East NGS Market (by End User)
  • 11.2.4 Growth Share Analysis for Asia-Pacific and Middle East NGS Market (by Throughput)
• 11.3 Company Profiles
  • 11.3.1 BGI Group
    • 11.3.1.1.1 Company Overview
    • 11.3.1.1.2 Product Portfolio
    • 11.3.1.1.3 Key Competitors
    • 11.3.1.1.4 Target Customers
    • 11.3.1.1.5 Analyst Perspective
  • 11.3.2 Illumina, Inc.
    • 11.3.2.1.1 Company Overview
    • 11.3.2.1.2 Product Portfolio
    • 11.3.2.1.3 Key Competitors
    • 11.3.2.1.4 Target Customers
    • 11.3.2.1.5 Analyst Perspective
  • 11.3.3 Thermo Fisher Scientific, Inc.
    • 11.3.3.1.1 Company Overview
    • 11.3.3.1.2 Product Portfolio
    • 11.3.3.1.3 Key Competitors
    • 11.3.3.1.4 Target Customers
    • 11.3.3.1.5 Analyst Perspective
  • 11.3.4 Pacific Biosciences of California, Inc.
    • 11.3.4.1.1 Company Overview
    • 11.3.4.1.2 Product Portfolio
    • 11.3.4.1.3 Key Competitors
    • 11.3.4.1.4 Target Customers
    • 11.3.4.1.5 Analyst Perspective
  • 11.3.5 Oxford Nanopore Technologies plc
    • 11.3.5.1.1 Company Overview
    • 11.3.5.1.2 Product Portfolio
    • 11.3.5.1.3 Key Competitors
    • 11.3.5.1.4 Target Customers
    • 11.3.5.1.5 Analyst Perspective
• 11.4 Emerging Companies (Asia-Pacific and Middle East)